2021
National Trends in Telestroke Utilization in a US Commercial Platform Prior to the COVID-19 Pandemic
Zachrison KS, Sharma R, Wang Y, Mehrotra A, Schwamm LH. National Trends in Telestroke Utilization in a US Commercial Platform Prior to the COVID-19 Pandemic. Journal Of Stroke And Cerebrovascular Diseases 2021, 30: 106035. PMID: 34419836, PMCID: PMC8494566, DOI: 10.1016/j.jstrokecerebrovasdis.2021.106035.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCOVID-19Databases, FactualFemaleFibrinolytic AgentsHumansMaleMiddle AgedPractice Patterns, Physicians'Quality ImprovementQuality Indicators, Health CareRemote ConsultationStrokeThrombolytic TherapyTime FactorsTime-to-TreatmentTissue Plasminogen ActivatorTreatment OutcomeUnited StatesConceptsIschemic stroke patientsTelestroke consultationAlteplase deliveryStroke patientsNumber of patientsNumber of consultsCOVID-19 public health emergencyPublic health emergencyAlteplase useMedian doorNeedle timeStroke severityED arrivalEmergency departmentImaging reviewHospital characteristicsTelestroke networkCT scanHospital participationSpoke sitesProvider groupsPatientsHospital sizeStudy periodHealth emergency
2020
Evaluation of stroke incidence with duty‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study
Hummel J, Verma A, Calkins H, Schwamm L, Gress D, Wells D, Souza J, Hokanson R, Hemingway L, Stromberg K, Hoyt R, Wickliffe A, DeLurgio D, Boersma L. Evaluation of stroke incidence with duty‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study. Journal Of Cardiovascular Electrophysiology 2020, 31: 1289-1297. PMID: 32270538, DOI: 10.1111/jce.14483.Peer-Reviewed Original ResearchConceptsDevice-related strokesAcute procedural successAtrial fibrillationAF trialSecondary outcomesStroke incidenceProcedural successAF studyStroke/transient ischemic attackVitamin K antagonist anticoagulationMajor structural heart diseasePulmonary vein stenosisTransient ischemic attackIncidence of strokeStructural heart diseaseNumber of patientsVitamin K antagonismAtrial fibrillation resultsRigorous clinical evaluationIDE trialIschemic attackNeurologist assessmentPersAF patientsAF burdenPV stenosis
2018
Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset
Etherton M, Barreto A, Schwamm L, Wu O. Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset. Frontiers In Neurology 2018, 9: 327. PMID: 29867736, PMCID: PMC5962731, DOI: 10.3389/fneur.2018.00327.Peer-Reviewed Original ResearchReperfusion therapyIschemic strokeSalvageable ischemic tissueAcute ischemic strokePivotal clinical trialsTreatment of patientsNumber of patientsRisk of infarctionLow treatment ratesUnwitnessed strokeIntravenous alteplaseEndovascular thrombectomyHospital arrivalStroke onsetRevascularization therapySalvageable tissueUnknown onsetClinical trialsClinical dilemmaIschemic tissueStroke researchPatientsTreatment ratesStrokeTherapy
2014
Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study
Gaggin H, Bhardwaj A, Belcher A, Motiwala S, Gandhi P, Simon M, Kelly N, Anderson A, Garasic J, Danik S, Schwamm L, Gerszten R, van Kimmenade R, Januzzi J. Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. IJC Metabolic & Endocrine 2014, 5: 11-18. DOI: 10.1016/j.ijcme.2014.08.005.Peer-Reviewed Original ResearchAcute kidney injuryEnd pointRenal complicationsMajor adverse cardiovascular eventsProspective single-center trialLong-term adverse outcomesPeri-procedural eventsPeripheral arterial complicationsAdverse cardiovascular eventsCombined end pointPeri-procedural complicationsPrimary end pointSecondary end pointsChronic kidney diseaseSingle-center trialNumber of patientsIndividual end pointsCardiovascular Disease StudyArterial complicationsAngiographic characteristicsCardiovascular eventsKidney injuryBaseline characteristicsNeurological eventsRenal biomarkers
2012
Economic Impact of Using Additional Diagnostic Tests to Better Select Patients With Stroke for Intravenous Thrombolysis in the United Kingdom
Earnshaw S, McDade C, Chapman A, Jackson D, Schwamm L. Economic Impact of Using Additional Diagnostic Tests to Better Select Patients With Stroke for Intravenous Thrombolysis in the United Kingdom. Clinical Therapeutics 2012, 34: 1544-1558. PMID: 22695225, DOI: 10.1016/j.clinthera.2012.05.004.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMRI selectionUsual careDiagnostic testsFavorable outcomeIncremental cost-effectiveness ratioAcute stroke treatmentPreferred diagnostic testNumber of patientsAdditional diagnostic testsCost-effectiveness ratioDecision analytic modelCTP selectionIntravenous thrombolysisStroke onsetStroke treatmentPatient selectionUK patientsPenumbral patternPatient outcomesPerfusion CTPatient historyThrombolysisPatientsPerfusion imaging
2011
Use of Telemedicine and Other Strategies to Increase the Number of Patients That May Be Treated with Intravenous Thrombolysis
Silva G, Schwamm L. Use of Telemedicine and Other Strategies to Increase the Number of Patients That May Be Treated with Intravenous Thrombolysis. Current Neurology And Neuroscience Reports 2011, 12: 10-16. PMID: 21997715, DOI: 10.1007/s11910-011-0235-6.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeUse of telemedicineIntravenous thrombolysisIschemic strokeIntravenous tissue plasminogen activator useAdult long-term disabilityTissue plasminogen activator useLong-term disabilityAmerican Heart AssociationNumber of patientsRecruitment of patientsRate of treatmentHelp of telemedicineThrombolysis trialsHeart AssociationStroke NetworkStroke systemsTelestroke networkTelestroke systemCurrent evidencePatientsThrombolysisStrokeCareTelemedicineAre Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation?
Reeves M, Grau-Sepulveda M, Fonarow G, Olson D, Smith E, Schwamm L. Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? Circulation Cardiovascular Quality And Outcomes 2011, 4: 503-511. PMID: 21828344, DOI: 10.1161/circoutcomes.111.961755.Peer-Reviewed Original ResearchConceptsGuidelines-Stroke programAtrial fibrillation/flutterIntravenous recombinant tissue plasminogen activator (rt-PA) therapyRecombinant tissue plasminogen activator therapyDeep vein thrombosis prophylaxisTissue plasminogen activator therapyBetter careTarget populationGWTG-Stroke hospitalsIschemic stroke admissionsPlasminogen activator therapyNumber of patientsProportion of subjectsData collection formDischarge antithromboticsEarly antithromboticsThrombosis prophylaxisTreatment contraindicationsEligible subjectsStroke admissionsActivator therapySmoking cessationLipid therapyMeasure complianceContraindications
2009
Case volumes of intra-arterial and intravenous treatment of ischemic stroke in the USA
Hirsch J, Yoo A, Nogueira R, Verduzco L, Schwamm L, Pryor J, Rabinov J, González R. Case volumes of intra-arterial and intravenous treatment of ischemic stroke in the USA. Journal Of NeuroInterventional Surgery 2009, 1: 27. PMID: 21994101, DOI: 10.1136/jnis.2009.000166.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyNumber of patientsT-PA useStroke centersIschemic strokeCase volumeStroke therapyIntra-arterial reperfusion therapyIntravenous tissue plasminogen activatorIntra-arterial stroke therapyPercentage of patientsLarge vessel occlusionCases/yearTissue plasminogen activatorMassachusetts General HospitalReperfusion therapyIntravenous treatmentStroke casesGeneral HospitalNumber of casesPatientsTherapyStrokeLiterature searchPlasminogen activator